Category List
North America CAR-T cell therapy market will reach US$ 3,360 Million in 2028 Details
CAR-T cell therapy is a complex and extremely costly cancer treatment across the globe. At present, only three CAR-T cell therapies have been approved by the regulatory authorities. In August 2017, FDA has approved Kymriah manufactured by Novartis for the treatment of patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia (ALL). Kymriah therapy cost is varied from country to country. Kymriah cost for a single treatment is around US$ 475 Thousand in the United States whereas, in Japan, it is around US$ 305 Thousand for a one-time infusion.
In October 2017 Gilead Science/Kite was the 2nd company that gets approval for another CAR-T cell therapy “Yescarta” by the US FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. It is CD19-directed genetically modified autologous T cell immunotherapy. Yescarta. The treatment cost for Yescarta is US$ 373 Thousand per treatment regimen in the United States. Recently in July 2020, Gilead Science/Kite gets the 2nd CAR-T cell therapy Tecartus approvals by the US FDA for the treatment of relapsed or refractory mantle cell lymphoma (MCL). To date, it is the only approved therapy for the treatment of MCL across the world.
According to the MNG Tracker research titled “Global CAR-T Cell Therapy Market by Application (Acute Lymphoblastic Leukaemia (ALL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM)), by Regions (North America, Europe, Asia Pacific, Latin America Middle East, Africa), by Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvIII, Others) Market Products (Yescarta, Kymriah)”, North America region holds the majority share in this market place. It is anticipated that the North America CAR-T cell therapy market will grow with significant CAGR during the forecasting period 2021-2028 and likely to touch US$ 3,360 Million in 2028. Asia Pacific market is expected to grow with the highest CAGR during the forecasting period.
Diffuse Large B Cell Lymphoma (DLBCL) is the leading therapeutic application in the global CAR-T cell therapy market
Acute Lymphoblastic Leukaemia (ALL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM) is therapeutic applications studies in the global CAR-T cell therapy market report by MNG Tracker. Diffuse Large B Cell Lymphoma (DLBCL) is the leading therapeutic application in the global CAR-T cell therapy market. It controls over half of the total market alone in 2020.
Antigen CD-19 holds the largest market in the global CAR-T cell therapy market
In this report, we have done a complete assessment of the global CAR-T cell therapy market based on antigens; CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvIII, Others. Antigen CD-19 holds the largest market in the global CAR-T cell therapy market as all approved therapies such as Kymriah, Yescarta and Tecartus are based on CD-19 antigen.
Global CAR-T cell therapy market – Growth Drivers & Challenges
Positive reimbursement decisions, the rise of CAR-T cell therapy in oncology and increasing incidence of cancer are some of the key drivers for the global CAR-T cell therapy market. The industry faces some challenges such as high upfront cost, complex manufacturing and supply chain, the limited number of certified academic medical centers (AMCs), etc.
